Mary Beth Scholand, MD

Journal Article

1. Gayen SK, Baughman RP, Nathan SD, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmoma EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, Shlobin OA, Gupta R (2023). Pulmonary hemodynamics and transplant-free survival in sarcoidosis-associated pulmonary hypertension: Results from an international registry. Pulm Circ, 13(4), e12297. (Read full article)
2. Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, Barnes H, Adegunsoye A, Azuma A, Chung L, Gardner GC, Highland KB, Hudson M, Kaner RJ, Kolb M, Scholand MB, Steen V, Thomson CC, Volkmann ER, Wigley FM, Burlile D, Kemper KA, Knight SL, Ghazipura M (2023). Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. (Read full article)
3. Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO, TRAIL1 Network Investigators (2022). Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med, 11(1), 87-96. (Read full article)
4. Saketkoo LA, Escorpizo R, Varga J, Keen KJ, Fligelstone K, Birring SS, Alexanderson H, Pettersson H, Chaudhry HA, Poole JL, Regardt M, LeSage D, Sarver C, Lanario J, Renzoni E, Scholand MB, Lammi MR, Kowal-Bielecka O, Distler O, Frech T, Shapiro L, Varju C, Volkmann ER, Bernstein EJ, Drent M, Obi ON, Patterson KC, Russell AM, Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis G-FoRSS (2022). World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease. Front Pharmacol, 13, 979788. (Read full article)
5. Saketkoo LA LA, Jensen K, Nikoletou D, Newton JJ, Rivera FJ, Howie M, Reese RK, Goodman M, Hart PB, Bembry W, Russell A, Lian I, Lammi MR, Scholand Mb MB, Russell Am AM (2022). Sarcoidosis Illuminations on Living During COVID-19: Patient Experiences of Diagnosis, Management, and Survival Before and During the Pandemic. J Patient Exp, 9, 23743735221075556. (Read full article)
6. Lee J, White E, Freiheit E, Scholand MB, Strek ME, Podolanczuk AJ, Patel NM, Pulmonary Fibrosis Foundation (2022). Cough-specific Quality of Life Predicts Disease Progression Among Patients with Interstitial Lung Disease: Data from the Pulmonary Fibrosis Foundation Patient Registry. Chest. (Read full article)
7. Gupta R, Baughman RP, Nathan SD, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmona EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, Shlobin OA (2022). The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respir Med, 196, 106801. (Read full article)
8. Rahaghi FF, Kolaitis NA, Adegunsoye A, de Andrade J, Flaherty KR, Lancaster L, Lee JS, Levine D, Preston IR, Safdar Z, Saggar R, Sahay S, Scholand MB, Shlobin O, Zisman DA, Nathan SD (2022). Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study. Chest, 162, 145-155. (Read full article)
9. Huitema MP, Post MC, Grutters JC, Wells AU, Kouranos V, Shlobin OA, Nathan SD, Culver DA, Barney J, Gupta R, Carmona E, Alhamad EH, Scholand MB, Wijsenbeek M, Ganesh S, Lower EE, Engel PJ, Baughman RP (2022). Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study. Sarcoidosis Vasc Diffuse Lung Dis, 38(4), e2021032. (Read full article)
10. Lasky JA, Case A, Unterman A, Kreuter M, Scholand MB, Chaudhary S, Lofaro LR, Johnson M, Huang J, Bhorade SM, Kennedy GC (2021). The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc, 19, 916-924. (Read full article)
11. Pettersson H, Alexanderson H, Poole JL, Varga J, Regardt M, Russell AM, Salam Y, Jensen K, Mansour J, Frech T, Feghali-Bostwick C, Varj C, Baldwin N, Heenan M, Fligelstone K, Holmner M, Lammi MR, Scholand MB, Shapiro L, Volkmann ER, Saketkoo LA (2021). Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). Best Pract Res Clin Rheumatol, 35, 101695. (Read full article)
12. Saketkoo LA, Russell AM, Jensen K, Mandizha J, Tavee J, Newton J, Rivera F, Howie M, Reese R, Goodman M, Hart P, Strookappe B, De Vries J, Rosenbach M, Scholand MB, Lammi MR, Elfferich M, Lower E, Baughman RP, Sweiss N, Judson MA, Drent M (2021). Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics (Basel), 11(6). (Read full article)
13. Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, Sciurba FC, Raghu G, Brooks MM, Kim DY, Dilling DF, Criner GJ, Kim H, Belloli EA, Nambiar AM, Scholand MB, Anstrom KJ, Noth I, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative (2021). Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. JAMA, 325(18), 1841-1851. (Read full article)
14. Maher TM, Costabel U, Glassberg MK, Kondoh Y, Ogura T, Scholand MB, Kardatzke D, Howard M, Olsson J, Neighbors M, Belloni P, Swigris JJ (2021). Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Eur Respir J, 57(2). (Read full article)
15. Richeldi L, Scholand MB, Lynch DA, Colby TV, Myers JL, Groshong SD, Chung JH, Benzaquen S, Nathan SD, Davis JR, Schmidt SL, Hagmeyer L, Sonetti D, Hetzel J, Criner GJ, Case AH, Ramaswamy M, Calero K, Gauhar UA, Patel NM, Lancaster L, Choi Y, Pankratz DG, Walsh PS, Lofaro LR, Huang J, Bhorade SM, Kennedy GC, Martinez FJ, Raghu G (2020). Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. Am J Respir Crit Care Med, 203(2), 211-220. (Read full article)
16. Swigris JJ, Andrae DA, Churney T, Johnson N, Scholand MB, White ES, Matsui A, Raimundo K, Evans CJ (2020). Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. Am J Respir Crit Care Med, 202(12), 1689-1697. (Read full article)
17. Rahaghi FF, Safdar Z, Brown AW, de Andrade JA, Flaherty KR, Kaner RJ, King CS, Padilla ML, Noth I, Scholand MB, Shifren A, Nathan SD (2020). Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulm Med, 20(1), 191. (Read full article)
18. Baughman RP, Scholand MB, Rahaghi FF (2020). Clinical phenotyping: role in treatment decisions in sarcoidosis. Eur Respir Rev, 29(155). (Read full article)
19. Rahaghi FF, Baughman RP, Saketkoo LA, Sweiss NJ, Barney JB, Birring SS, Costabel U, Crouser ED, Drent M, Gerke AK, Grutters JC, Hamzeh NY, Huizar I, Ennis James W 4th, Kalra S, Kullberg S, Li H, Lower EE, Maier LA, Mirsaeidi M, Mller-Quernheim J, Carmona Porquera EM, Samavati L, Valeyre D, Scholand MB (2020). Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev, 29(155). (Read full article)
20. Rahaghi FF, Sweiss NJ, Saketkoo LA, Scholand MB, Barney JB, Gerke AK, Lower EE, Mirsaeidi M, OHare L, Rumbak MJ, Samavati L, Baughman RP (2020). Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. Eur Respir Rev, 29(155). (Read full article)
21. Saketkoo LA, Scholand MB, Lammi MR, Russell AM (2020). Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials. J Scleroderma Relat Disord, 5(2 Suppl), 48-60. (Read full article)
22. Richeldi L, Fernndez Prez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G (2019). Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med, 8(1), 25-33. (Read full article)
23. Patel NM, Kulkarni T, Dilling D, Scholand MB, Interstitial and Diffuse Lung Disease Network Steering Committee (2019). Preoperative Evaluation of Patients With Interstitial Lung Disease. Chest, 156(5), 826-833. (Read full article)
24. Wuyts W, Antin-Ozerkis D, Huggins JT, LaCamera PP, Spagnolo P, Vakov M, Wijsenbeek MS, Polman B, Kirchgaessler KU, Scholand MB (2019). Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. Respir Med, 150, 120-125. (Read full article)

Review

1. Balakrishnan B, Callahan SJ, Cherian SV, Subramanian A, Sarkar S, Bhatt N, Scholand MB (2023). Climate Change for the Pulmonologist: A Focused Review. [Review]. Chest. (Read full article)
2. Saketkoo LA, Frech T, Varj C, Domsic R, Farrell J, Gordon JK, Mihai C, Sandorfi N, Shapiro L, Poole J, Volkmann ER, Lammi M, McAnally K, Alexanderson H, Pettersson H, Hant F, Kuwana M, Shah AA, Smith V, Hsu V, Kowal-Bielecka O, Assassi S, Cutolo M, Kayser C, Shanmugam VK, Vonk MC, Fligelstone K, Baldwin N, Connolly K, Ronnow A, Toth B, Suave M, Farrington S, Bernstein EJ, Crofford LJ, Czirjk L, Jensen K, Hinchclif M, Hudson M, Lammi MR, Mansour J, Morgan ND, Mendoza F, Nikpour M, Pauling J, Riemekasten G, Russell AM, Scholand MB, Seigart E, Rodriguez-Reyna TS, Hummers L, Walker U, Steen V (2021). A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. [Review]. Best Pract Res Clin Rheumatol, 35(3), 101707. (Read full article)

Case Report

1. Werst D, Scarpato B, Callahan SJ, Scholand MB (2020). A 64-Year-Old Man With Multifocal Infiltrates. Chest, 159(3), e151-e154. (Read full article)

Letter

1. Scholand MB, Wells AU (2022). Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults. [Letter to the editor]. Am J Respir Crit Care Med, 206(10), 1296. (Read full article)
2. Saketkoo LA, Alexanderson H, Lammi MR, LeSage D, Jensen K, Scholand MB, Volkmann ER, Russell AM (2020). An ode to the primal tonic of dance-congratulating the Life of Breath project. [Letter to the editor]. Lancet Respir Med, 8(12), e90-e91. (Read full article)

News

• U of U Health abre Clínica Integral para efectos a largo plazo de COVID-19

• Testing Inhaled Treprostinil in People with Idiopathic Pulmonary Fibrosis
• Inhaled Treprostinil: A Study Drug for People with Fibrotic Lung Disease
• Testing the Drug Nintedanib for Adults with Myositis Interstitial Lung Disease
• Testing Efzofitimod for Adults with Systemic Sclerosis Related Interstitial Lung Disease
• Testing a Study Drug, BMS-986278 for People with Idiopathic Pulmonary Fibrosis
• Testing a Study Drug BMS-986278 for People with Progressive Pulmonary Fibrosis
• Testing a Study Drug Bexotegrast for People with Idiopathic Pulmonary Fibrosis
• Testing a Study Drug Vixarelimab for People with Idiopathic Pulmonary Fibrosis and People with Systemic Sclerosis-Associated Interstitial Lung Disease
• Testing an Inhaled Study Drug Treprostinil for People with Progressive Pulmonary Fibrosis